Figure 4.
Risk of hospitalisation associated with immunosuppressive drug class exposure (selective immunosuppressants, tumour necrosis factor inhibitors, interleukin inhibitors, calcineurin inhibitors, systemic corticosteroids, and other immunosuppressants including rituximab) in patients with immune-mediated inflammatory diseases (IMID).